Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 10/20 | 0.45 |
| ▸ | PPARA | Q07869 | 6/20 | 0.45 |
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.35 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2966850 | 1.00 | SLC16A3 (0.46) | SLC16A3PPARGPPARAELANETP53 | |
| SCHEMBL2980508 | 0.93 | SLC16A3 (0.46) | SLC16A3PPARGPPARAELANEPTGER4 | |
| SCHEMBL2980502 | 0.93 | SLC16A3 (0.46) | SLC16A3PPARGPPARAELANEPTGER4 | |
| SCHEMBL2981026 | 0.92 | SLC16A3 (0.47) | SLC16A3PPARGPPARAELANEPTGER4 | |
| SCHEMBL2981028 | 0.92 | SLC16A3 (0.47) | SLC16A3PPARGPPARAELANEPTGER4 | |
| SCHEMBL2986308 | 0.86 | SLC16A3 (0.50) | SLC16A3PPARGPPARATP53PTGER4 | |
| SCHEMBL2986311 | 0.86 | SLC16A3 (0.50) | SLC16A3PPARGPPARATP53PTGER4 | |
| SCHEMBL2982119 | 0.84 | PPARG (0.37) | PPARGPPARAELANETP53PTGER4 | |
| SCHEMBL2982121 | 0.84 | PPARG (0.37) | PPARGPPARAELANETP53PTGER4 | |
| SCHEMBL2972623 | 0.82 | TP53 (0.48) | SLC16A3PPARGPPARATP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781479-B2 | Heteroaryl derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-20080167306-A1 | Novel Heteroaryl Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1837329-A1 | NOVEL HETEROARYL DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167306-A1 | Novel Heteroaryl Derivative | GPR119, SLC2A4, SLC5A2 | SLC16A3 1940/4885PPARG 498/4885PPARA 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.